-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $37

Benzinga·10/07/2026 15:07:13
Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $39 to $37.